Company news

Johnson & Johnson news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 12, 2026

Talvey (Johnson & Johnson: talquetamab-tgvs) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

May 11, 2026

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 11, 2026

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 7, 2026

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

May 5, 2026

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 5, 2026

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 4, 2026

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

April 30, 2026

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

April 27, 2026

FDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia

April 27, 2026

Viz.ai Announces Strategic Collaboration to Expand Access to AI-Powered Subdural Hemorrhage Care

April 23, 2026

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

April 22, 2026

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

April 22, 2026

[Latest] Global Surgical Drill Bits Market Size/Share Worth USD 540 Million by 2035 at a 5.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

April 21, 2026

National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others

April 20, 2026

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

April 16, 2026

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

April 14, 2026

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

April 14, 2026

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

April 10, 2026

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

April 7, 2026

NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

March 30, 2026

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

March 28, 2026

Johnson & Johnson’s DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

March 27, 2026

Global Baby Powder Market to Reach USD 2.0 billion by 2036 at 5% CAGR, India & Johnson & Johnson Lead Growth

March 26, 2026

Origin Announces HP Embalagens as Strategic Distributor for Sustainable PET Bottlecaps

March 19, 2026

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

March 18, 2026

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

March 16, 2026

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

March 13, 2026

Rybrevant (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

March 13, 2026

Zabdeno (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

March 13, 2026

Tecvayli (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

March 13, 2026

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

March 12, 2026

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

March 6, 2026

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

March 5, 2026

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

March 3, 2026

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

March 2, 2026

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

February 26, 2026

Johnson & Johnson Enterprise Technology Analysis Report 2025: Accelerators, Digital Strategies, Innovation Programs, Incubators, Technology Initiatives, Partnerships, Investment & Acquisition

February 25, 2026

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

February 24, 2026

Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

February 23, 2026

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

February 21, 2026

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

February 19, 2026

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

February 18, 2026

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

February 17, 2026

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens[1] for Astigmatic Adults living with Presbyopia

February 9, 2026

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

February 6, 2026

Johnson & Johnson Named Inaugural Global Impact Award Winner by the Healthcare Businesswomen's Association (HBA)

February 5, 2026

Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months

February 2, 2026

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

January 27, 2026

← Newer news releases · Older news releases →

Calls

The 5 newest of 31 calls. Every call is listed under its year.

Decks

The 5 newest of 69 decks. Every deck is listed under its year.